The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
Open accessAbstract
Successful adoptive T-cell immunotherapy of solid tumors will require improved expansion and cytotoxicity of tumor-directed T cells within tumors. Providing recombinant or transgenic cytokines may produce the desired benefits but is associated with significant toxicities, constraining clinical use. To circumvent this limitation, we constructed a constitutively signaling cytokine receptor, C7R, which potently triggers the IL7 signaling axis but is unresponsive to extracellular cytokine. This strategy augments modified T-cell function following antigen exposure, but avoids stimulating bystander lymphocytes. Coexpressing the C7R with a tumor-directed chimeric antigen receptor (CAR) increased T-cell proliferation, survival, and antitumor activity during repeated exposure to tumor cells, without T-cell dysfunction or autonomous T-cell growth. Furthermore, C7R-coexpressing CAR T cells were active against metastatic neuroblastoma and orthotopic glioblastoma xenograft models even at cell doses that had been ineffective without C7R support. C7R may thus be able to enhance antigen-specific T-cell therapies against cancer. Significance: The constitutively signaling C7R system developed here delivers potent IL7 stimulation to CAR T cells, increasing their persistence and antitumor activity against multiple preclinical tumor models, supporting its clinical development. Cancer Discov; 7(11); 1238–47. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 1201
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596 · cited 1×
“Recently, constitutively active IL-7 receptors have been reported to transmit IL-7 signaling without the need for ligand or the common receptor gamma chain (γc), as a result of IL-7Rα homodimerization due to cysteine and/or proline insertions in the transmembrane domain (13,14).”
BackgroundInducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · cited 2×
“iC9-2A-CD19t: The vector was generated as previously described elsewhere (28).”
BackgroundMethodSelf-citationDudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,332
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Self-citationLouis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
Self-citationThe Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
Xu, Y., Zhang, M., Ramos, C. A., Durett, A., Liu, E., Dakhova, O., Liu, H., Creighton, C. J., Gee, A. P., Heslop, H. E., et al. (2014) · Blood · doi:10.1182/blood-2014-01-552174 · Cited by 744
Self-citationConlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Life and death in peripheral T cells
Krammer, P. H., Arnold, R., & Lavrik, I. N. (2007) · Nature Reviews Immunology · doi:10.1038/nri2115 · Cited by 653
Bcl-2 Rescues T Lymphopoiesis in Interleukin-7 Receptor–Deficient Mice
Akashi, K., Kondo, M., von Freeden-Jeffry, U., Murray, R., & Weissman, I. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80291-3 · Cited by 593
Harnessing the biology of IL-7 for therapeutic application
Mackall, C. L., Fry, T. J., & Gress, R. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2970 · Cited by 571
Gene-engineered T cells for cancer therapy
Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3565 · Cited by 505
Maraskovsky, E., O'Reilly, L. A., Teepe, M., Corcoran, L. M., Peschon, J. J., & Strasser, A. (1997) · Cell · doi:10.1016/s0092-8674(00)80289-5 · Cited by 493
Hurton, L. V., Singh, H., Najjar, A. M., Switzer, K. C., Mi, T., Maiti, S., Olivares, S., Rabinovich, B., Huls, H., Forget, M.-A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610544113 · Cited by 461
The genetics and mechanisms of T cell acute lymphoblastic leukaemia
Belver, L., & Ferrando, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.63 · Cited by 446
Zhang, L., Morgan, R. A., Beane, J. D., Zheng, Z., Dudley, M. E., Kassim, S. H., Nahvi, A. V., Ngo, L. T., Sherry, R. M., Phan, G. Q., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2085 · Cited by 444
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia
Zenatti, P. P., Ribeiro, D., Li, W., Zuurbier, L., Silva, M. C., Paganin, M., Tritapoe, J., Hixon, J. A., Silveira, A. B., Cardoso, B. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.924 · Cited by 416
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
Philip, B., Kokalaki, E., Mekkaoui, L., Thomas, S., Straathof, K., Flutter, B., Marin, V., Marafioti, T., Chakraverty, R., Linch, D., et al. (2014) · Blood · doi:10.1182/blood-2014-01-545020 · Cited by 397
Shochat, C., Tal, N., Bandapalli, O. R., Palmi, C., Ganmore, I., te Kronnie, G., Cario, G., Cazzaniga, G., Kulozik, A. E., Stanulla, M., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110580 · Cited by 351
Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages
Song, L., Asgharzadeh, S., Salo, J., Engell, K., Wu, H.-W., Sposto, R., Ara, T., Silverman, A. M., DeClerck, Y. A., Seeger, R. C., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37869 · Cited by 342
Self-citationHeczey, A., Liu, D., Tian, G., Courtney, A. N., Wei, J., Marinova, E., Gao, X., Guo, L., Yvon, E., Hicks, J., et al. (2014) · Blood · doi:10.1182/blood-2013-11-541235 · Cited by 318
Self-citationIL-7: maintaining T-cell memory and achieving homeostasis
Bradley, L. M., Haynes, L., & Swain, S. L. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.01.004 · Cited by 270
Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool
Melchionda, F., Fry, T. J., Milliron, M. J., McKirdy, M. A., Tagaya, Y., & Mackall, C. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523134 · Cited by 246
T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
Chow, K. K., Naik, S., Kakarla, S., Brawley, V. S., Shaffer, D. R., Yi, Z., Rainusso, N., Wu, M.-F., Liu, H., Kew, Y., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.210 · Cited by 245
Self-citationMarkley, J. C., & Sadelain, M. (2010) · Blood · doi:10.1182/blood-2009-09-241398 · Cited by 228
Pellegrini, M., Calzascia, T., Elford, A. R., Shahinian, A., Lin, A. E., Dissanayake, D., Dhanji, S., Nguyen, L. T., Gronski, M. A., Morre, M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1953 · Cited by 228
Sportès, C., Babb, R. R., Krumlauf, M. C., Hakim, F. T., Steinberg, S. M., Chow, C. K., Brown, M. R., Fleisher, T. A., Noel, P., Maric, I., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1303 · Cited by 227
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo
Tian, G., Courtney, A. N., Jena, B., Heczey, A., Liu, D., Marinova, E., Guo, L., Xu, X., Torikai, H., Mo, Q., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83476 · Cited by 173
Self-citationLiu, D., Song, L., Wei, J., Courtney, A. N., Gao, X., Marinova, E., Guo, L., Heczey, A., Asgharzadeh, S., Kim, E., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59535 · Cited by 164
Self-citationQuintarelli, C., Vera, J., Savoldo, B., Giordano-Attianese, G., Pule, M., Foster, A., Heslop, H., Rooney, C., Brenner, M., & Dotti, G. (2007) · Blood · doi:10.1182/blood-2007-02-072843 · Cited by 164
Self-citationOncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma
Song, L., Ara, T., Wu, H., Woo, C., Reynolds, C. P., Seeger, R. C., DeClerck, Y. A., Thiele, C. J., Sposto, R., & Metelitsa, L. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30751 · Cited by 123
Self-citationObenaus, M., Leitão, C., Leisegang, M., Chen, X. T., Gavvovidis, I., van der Bruggen, P., Uckert, W., Schendel, D. J., & Blankenstein, T. J. F. (2015) · Nature Biotechnology · doi:10.1038/nbt.3147 · Cited by 103
Effects of IL-7 on memory CD8+ T cell homeostasis are influenced by the timing of therapy in mice
Nanjappa, S. G., Walent, J. H., Morre, M., & Suresh, M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32020 · Cited by 96
Genetic Manipulation of Tumor-specific Cytotoxic T Lymphocytes to Restore Responsiveness to IL-7
Vera, J. F., Hoyos, V., Savoldo, B., Quintarelli, C., Attianese, G. M. P. G., Leen, A. M., Liu, H., Foster, A. E., Heslop, H. E., Rooney, C. M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.34 · Cited by 94
Self-citationSingh, N., Liu, X., Hulitt, J., Jiang, S., June, C. H., Grupp, S. A., Barrett, D. M., & Zhao, Y. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0051 · Cited by 84
Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells
Liu, D., Song, L., Brawley, V. S., Robison, N. J., Wei, J., Gao, X., Tian, G., Margol, A., Ahmed, N. M., Asgharzadeh, S., et al. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.06.005 · Cited by 69
Self-citationYokoyama, K., Yokoyama, N., Izawa, K., Kotani, A., Harashima, A., Hozumi, K., & Tojo, A. (2013) · Blood · doi:10.1182/blood-2012-08-451278 · Cited by 37
Cited by
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
Clinical lessons learned from the first leg of the CAR T cell journey
Majzner, R. G., & Mackall, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0564-6 · Cited by 636
Metadata
- Authors
- Shum, T., Omer, B., Tashiro, H., Kruse, R. L., Wagner, D. L., Parikh, K., Yi, Z., Sauer, T., Liu, D., Parihar, R., Castillo, P., Liu, H., Brenner, M. K., Metelitsa, L. S., Gottschalk, S., & Rooney, C. M.
- Venue
- Cancer Discovery
- Published
- 2017-11-01
- Volume
- 7
- Issue
- 11
- Pages
- 1238-1247
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2747383311
- Cited by
- 297
- References
- 43
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.